Header Logo

Connection

MICHAEL A DAVIES to Proto-Oncogene Proteins B-raf

Back to Details
This is a "connection" page, showing publications MICHAEL A DAVIES has written about Proto-Oncogene Proteins B-raf.
MICHAEL A DAVIES
Connection Strength
4.569
Proto-Oncogene Proteins B-raf
  1. Primary medical therapy for BRAFV600E-mutant melanoma brain metastases-is this good enough? - Authors' reply. Lancet Oncol. 2017 09; 18(9):e509.
    View in: PubMed
    Score: 0.369
  2. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017 07; 18(7):863-873.
    View in: PubMed
    Score: 0.363
  3. Molecular approaches to tumor inhibition in melanoma. Clin Adv Hematol Oncol. 2015 Dec; 13(12):831-3.
    View in: PubMed
    Score: 0.327
  4. BRAF in early stage melanoma: rationale for testing and treatment? Br J Dermatol. 2015 Jul; 173(1):9-10.
    View in: PubMed
    Score: 0.317
  5. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014 Nov 01; 20(21):5527-36.
    View in: PubMed
    Score: 0.299
  6. Finding the right balance of BRAF inhibition in melanoma. Cancer Discov. 2014 May; 4(5):510-2.
    View in: PubMed
    Score: 0.293
  7. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol. 2014 Feb 01; 87(3):381-9.
    View in: PubMed
    Score: 0.284
  8. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer. 2013 Nov 01; 119(21):3821-9.
    View in: PubMed
    Score: 0.278
  9. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 2010 Nov 01; 70(21):8736-47.
    View in: PubMed
    Score: 0.229
  10. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
    View in: PubMed
    Score: 0.129
  11. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer. 2020 02 01; 126(3):523-530.
    View in: PubMed
    Score: 0.107
  12. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
    View in: PubMed
    Score: 0.079
  13. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunol Res. 2015 Jun; 3(6):602-9.
    View in: PubMed
    Score: 0.078
  14. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1a and oxidative phosphorylation in melanoma. Cancer Res. 2014 Dec 01; 74(23):7037-47.
    View in: PubMed
    Score: 0.075
  15. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
    View in: PubMed
    Score: 0.075
  16. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res. 2014 Sep 01; 74(17):4845-4852.
    View in: PubMed
    Score: 0.074
  17. Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Hematol Oncol Clin North Am. 2014 Jun; 28(3):523-36.
    View in: PubMed
    Score: 0.074
  18. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res. 2014 Nov 01; 20(21):5537-46.
    View in: PubMed
    Score: 0.073
  19. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest. 2014 Mar; 124(3):1406-17.
    View in: PubMed
    Score: 0.072
  20. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2013 Sep 01; 19(17):4868-78.
    View in: PubMed
    Score: 0.069
  21. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn. 2013 Mar; 15(2):220-6.
    View in: PubMed
    Score: 0.067
  22. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013 Feb 01; 19(3):657-67.
    View in: PubMed
    Score: 0.067
  23. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403.
    View in: PubMed
    Score: 0.066
  24. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov; 13(11):1087-95.
    View in: PubMed
    Score: 0.066
  25. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer. 2013 Feb 15; 119(4):799-805.
    View in: PubMed
    Score: 0.065
  26. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012 Oct 01; 18(19):5329-40.
    View in: PubMed
    Score: 0.065
  27. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol. 2012 Sep; 39(9):821-5.
    View in: PubMed
    Score: 0.065
  28. The role of the PI3K-AKT pathway in melanoma. Cancer J. 2012 Mar-Apr; 18(2):142-7.
    View in: PubMed
    Score: 0.063
  29. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res. 2012 Feb 15; 18(4):1120-8.
    View in: PubMed
    Score: 0.062
  30. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother. 2012 Jan; 35(1):66-72.
    View in: PubMed
    Score: 0.062
  31. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012 Aug 15; 118(16):4014-23.
    View in: PubMed
    Score: 0.062
  32. Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am. 2011 Jan; 20(1):165-80.
    View in: PubMed
    Score: 0.058
  33. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.
    View in: PubMed
    Score: 0.031
  34. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
    View in: PubMed
    Score: 0.021
  35. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Res. 2015 Sep 01; 75(17):3554-67.
    View in: PubMed
    Score: 0.020
  36. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62.
    View in: PubMed
    Score: 0.020
  37. A landscape of driver mutations in melanoma. Cell. 2012 Jul 20; 150(2):251-63.
    View in: PubMed
    Score: 0.016
  38. Association of activated c-Met with NRAS-mutated human melanomas. Int J Cancer. 2012 Jul 15; 131(2):E56-65.
    View in: PubMed
    Score: 0.016
  39. Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res. 2009 Apr 15; 15(8):2872-8.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.